Clinical features, diagnosis incl specimen collection

Warning

Clinical features

Signs and symptoms in men:

  • mucopurulent/purulent urethral discharge
  • dysuria
  • anal discharge
  • perianal/anal pain or discomfort
  • epididymal tenderness/swelling
  • balanitis.

 

Signs and symptoms in women:

  • often no signs or symptoms are present
  • increased/altered vaginal discharge
  • pelvic/lower abdominal tenderness/pain
  • dysuria
  • mucopurulent endocervical discharge
  • easily induced endocervical bleeding
  • intermenstrual bleeding/ menorrhagia (rarely).

 

Complications:

  • epididymitis
  • prostatitis
  • endometritis
  • pelvic inflammatory disease (PID)
  • haematogenous dissemination leading to skin lesions, arthralgia, arthritis, and tenosynovitis.

 

Diagnosis

1. Microscopy

Gram negative intracellular diplococci
(NB Microscopy provides a provisional diagnosis – always make this clear. Final diagnosis is the result of the PCR and/or culture)

If microscopy not available on site, dry the slide on a hotplate/airdry and transport as per guideline for gram-stain and microscopy at local lab.

2. NAAT

Nucleic acid amplification testing (NAAT) is a new technique which facilitates less invasive testing and examination.

NAAT testing is emerging as the primary method of excluding gonorrhoea from ano-genital and pharyngeal sites (although not yet licensed for use in rectum and pharynx).

A positive result from a GC NAAT should always, with patient consent, have a culture swab by repeat sampling, prior to treatment and sending the specimen to the appropriate bacteriology lab for direct plating. This allows antibiotic susceptibility testing and resistant strains can be identified.

There is a small risk of false positives with NAAT testing. Counselling/ partner notification should take this into account, especially if the clinical likelihood is low.

The test sensitivity in female urine is significantly lower, therefore urine is not the optimal specimen in women.

 

3. Culture

When doing a culture for GC, a NAAT test (if available in your health board) should be performed at the same time. Culture is used for:

  • Clinical locations where NAAT testing is unavailable
  • Any genital or rectal discharge
  • Suspected PID / cervicitis
  • Contacts of gonorrhoea – prior to epidemiological treatment.
  • Pharyngeal specimens (pending further validation).
  • Rectal samples in men who have sex with men (MSM).
  • Any NAAT-positive case with no previous culture performed (state on request that NAAT positive).

 

The following table shows which tests should be taken:

Please note that NAAT testing on rectal and pharyngeal swabs has not been validated. Microscopy, if available, should be done at symptomatic sites (cervix, urethra and rectal).

Anatomical site being tested

Type of specimen

Heterosexual male

Men who have sex with men

Female

Throat/ pharynx

Throat swab for GC/chlamydia NAAT

*

(if sexual history dictates or symptomatic at this site)

*

Throat swab for GC culture

*

*

*

Urethra

First void urine for GC/chlamydia NAAT

*

Charcoal urethral swab for GC culture

*

*

*

Female genital tract

Self obtained low vaginal swab for GC/chlamydia NAAT

N/A

N/A

√ (if asymptomatic and not being examined)

Endocervical charcoal swab for GC culture

N/A

N/A

*

Endocervical swab for GC/chlamydia NAAT

N/A

N/A

√If symptomatic at this site or being examined eg smear

Rectum

Perform proctoscopy if symptomatic

Rectal swab for GC/chlamydia NAAT

*

(if sexual history dictates or symptomatic at this site

*

Charcoal rectal swab for GC culture

*

*

*

*Take test if one or more of the following criteria are met. Client is:

  • symptomatic from this site
  • GC NAAT positive at this site
  • gonorrhoea contact at this site
  • post sexual assault and penetration has occurred in these sites.

Instructions for specimen collection

Urine:

10mls first void urine  in a plain universal container. The patient must not have urinated for at least one hour (or 2 hrs for some kits).

NB: technique should be carefully explained to patient, to ensure that the correct sample is obtained.

NB: Do not insert urinalysis dipsticks in the sample, as it may introduce contamination and adversely affect the amplification process.


Cervix:

Remove visible mucopus first, then firmly rotate in cervical os and over squamo-columnar junction. Try and avoid bleeding which can reduce sensitivity.


Vulvovaginal swab:

This may be self taken by patient (self obtained vulvo-vaginal swab - SOLVS) or by the clinician.
Insert the dry swab approx 5 cm into the vagina and gently rotate the swab for 10 to 30 seconds according to local manufacturers instructions. Bleeding may reduce sensitivity.


Pharyngeal swab:

Rub the swab over the posterior pharynx and tonsillar crypts.


Rectal swab:

  • Proctoscopy: The swab should be rubbed against the rectal wall.
  • Blind: The swab should be inserted 3cm into the anus and rotated for 10 to 30 seconds.

There have been incidences of the swab which comes with the kit breaking in the rectum. Clinicians may prefer, therefore, to use a separate swab with no breaking point on it.

In certain circumstances, a self collected rectal swab is acceptable.

 

Editorial Information

Last reviewed: 30/05/2024

Next review date: 30/05/2026

Author(s): West of Scotland Managed Clinical Network for Sexual Health Clinical Guidelines Group.

Version: 5.1

Approved By: West of Scotland Managed Clinical Network for Sexual Health